Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Vifor Pharma    VIFN   CH0364749348


SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

Vifor Pharma : Pioneering Project for Pharmaceutics – Vifor Pharma and the University of Basel are Jointly Establishing the World's First Research Professorship for Nanopharmaceutical and Regulatory Science

05/26/2019 | 03:01am EST

Public-private partnership is intended to safeguard Switzerland’s competitive position in pharmaceutical technologies of the future

Nanopharmaceutics promises ground-breaking innovation in the development of medicines:

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190526005014/en/

  • The Vifor Pharma Group is endowing two professorships for Nanopharmaceutical and Regulatory Science at the University of Basel
  • The commitment by Vifor Pharma and the University of Basel is aimed at ensuring Switzerland has the specialist knowledge and equipment needed to compete globally in this important emerging area of life sciences
  • With this decision, Vifor Pharma is demonstrating its commitment to Switzerland as a world-leading location for pharmaceutical research and development

Nanomedicines are playing an increasingly important role in the development of innovative new medications. These drugs are able to overcome specific cellular barriers in the human body with a view to targeting their effect even more precisely. Nanopharmacy therefore promises to help advance medical science and bring significant benefit to patients.

At present, however, researchers are only just beginning to acquire the in-depth scientific insights needed for a fundamental understanding of the development of nanomedicines, their applications and especially the regulatory requirements for their approval across Europe and worldwide. Likewise, there is a lack of experts with the necessary specialist knowledge – and these experts are urgently needed in industry, at regulatory authorities and in medical practice, including in Switzerland. As with other areas of cutting-edge research, this will take the form of a global race: those able to present findings as quickly as possible will be able to assert themselves as a centre of excellence in nanopharmaceutics.

Spread over 10 years, the commitment of CHF 10 million by the Vifor Pharma Group is intended to establish the field of nanopharmacy research at the University of Basel and to support the training of corresponding experts. The newly-created professorships in Nanopharmaceutical and Regulatory Science will be based at the Department of Pharmaceutical Sciences. There are also plans to establish and develop an internationally renowned Excellence Platform for the development, authorisation and application of nanopharmaceuticals, as well as the training of experts in the field.

Vifor Pharma views its contribution as start-up funding for this Excellence Platform, which is supported and jointly endorsed by stakeholders from academia, industry and public authorities. The aim is for the platform to both focus on research and teaching, and also to seek out international partnerships, organise conferences and incorporate additional sponsors with a view to becoming a leading international centre for nanopharmacy. “In order to make rapid progress in nanopharmaceutics, we’re reliant on clear and scientifically sound parameters for authorisation and patient safety,” says Etienne Jornod, Executive Chairman of the Board of Directors at Vifor Pharma. “The field of nanopharmacy is growing quickly, and it’s important to secure a leading position in this innovative area of medicine with the help of qualified experts. That’s why we want to help ensure that Switzerland establishes a strong research foundation in this emerging area of pharmaceutical development.”

For the University of Basel, this collaboration marks an important step in the further development of its life sciences focal area. “We’re proud to be able to develop this promising field of research in collaboration with a major industrial partner,” says Professor Andrea Schenker-Wicki, President of the University of Basel. “The crucial thing here is that we’re not only developing the scientific foundations, but also training the experts who will take this knowledge with them into industry and public authorities.” It is, she says, a key step for Basel and Switzerland in terms of their ability to compete on the international stage.

Vifor Pharma Group is a global pharmaceuticals company headquartered in Switzerland. It aims to become the global leader in iron deficiency, nephrology and cardio-renal therapies. The company is the partner of choice for pharmaceuticals and innovative patient-focused solutions. The Vifor Pharma Group strives to help patients around the world with severe and chronic diseases lead better, healthier lives. The company develops, manufactures and markets pharmaceutical products for precision patient care. The Vifor Pharma Group holds a leading position in all its core business activities and consists of the following companies: Vifor Pharma; Vifor Fresenius Medical Care Renal Pharma (a joint company with Fresenius Medical Care); Relypsa; and OM Pharma. The Vifor Pharma Group is listed on the Swiss Stock Exchange (SIX Swiss Exchange, VIFN, ISIN: CH0364749348).
For more information, please visit www.viforpharma.com.
In Switzerland Vifor Pharma has four production and research & development sites where the vast majority of medications are produced. Together with company headquarters, these sites employ over 1,300 people in Switzerland. The affiliate Vifor Pharma Switzerland is operating out of Villars-sur-Glâne in the French speaking part of the country.

The University of Basel has an international reputation of outstanding achievements in research and teaching. Founded in 1460, the University of Basel is the oldest university in Switzerland and has a history of success going back over 550 years.
As a comprehensive university offering a wide range of high-quality educational opportunities, the University of Basel attracts students from Switzerland and the entire world, offering them outstanding studying conditions as they work towards their bachelor’s, master’s or PhD degrees. Today, the University of Basel has around 13,000 students from over a hundred nations, including 2,800 PhD students. The University of Basel has seven faculties covering a wide spectrum of academic disciplines. At the same time, the university has positioned itself amidst the international competition in the form of five strategic focal areas: Life Sciences, Visual Studies, Nanosciences, Sustainability and Energy Research and European and Global Studies. In international rankings, the University of Basel is regularly placed among the 100 top universities in the world thanks to its research achievements.
The University of Basel has deep roots in the economically powerful and culturally rich Basel region. The university also works closely with domestic and international partners to make relevant contributions to the advancement of the sciences and society. This also means that the University of Basel pays particular attention to aspects of sustainability, equal opportunity and knowledge transfer.

© Business Wire 2019
All news about VIFOR PHARMA
11/27Swiss drugmaker Vifor had bid interest but talks halted - sources
11/26VIFOR PHARMA : supports Iron Deficiency Day 2020 to highlight global impact on h..
11/19VIFOR PHARMA : VFMCRP and Fresenius Kabi expand collaboration in nephrology in C..
11/16VIFOR PHARMA : Full results from affirm-ahf study show ferinject significantly r..
11/13VIFOR PHARMA : Full Results From AFFIRM-AHF Study Show Ferinject® Significantly ..
11/09Switzerland's Vifor strikes kidney drug deal with Angion
11/09VIFOR PHARMA : and Angion Sign License Agreement for ANG-3777 in Nephrology Indi..
11/04ChemoCentryx and VFMCRP announce European Medicines Agency has accepted to re..
11/03VIFOR PHARMA : VFMCRP and ChemoCentryx announce European Medicines Agency has ac..
10/21Vifor Pharma and Cara Therapeutics sign US license agreement for IV Korsuva t..
More news
Sales 2020 1 884 M 2 082 M 2 082 M
Net income 2020 291 M 321 M 321 M
Net cash 2020 397 M 439 M 439 M
P/E ratio 2020 28,8x
Yield 2020 1,57%
Capitalization 8 589 M 9 495 M 9 488 M
EV / Sales 2020 4,35x
EV / Sales 2021 3,92x
Nbr of Employees 2 733
Free-Float 71,8%
Duration : Period :
Vifor Pharma Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VIFOR PHARMA
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 13
Average target price 146,58 CHF
Last Close Price 132,35 CHF
Spread / Highest target 43,6%
Spread / Average Target 10,8%
Spread / Lowest Target -9,33%
EPS Revisions
Stefan Schulze President, Chief Executive & Operating Officer
Jacques Theurillat Chairman
Colin Bond Chief Financial Officer
Klaus Henning Jensen Chief Medical Officer
Etienne Jornod Honorary Chairman
Sector and Competitors
1st jan.Capitalization (M$)
VIFOR PHARMA-25.08%9 495
ORION OYJ-3.10%6 712